rs28364997
Variant summary
Our verdict is Likely benign. The variant received -3 ACMG points: 0P and 3B. BP4_ModerateBS1_Supporting
The NM_001044.5(SLC6A3):c.1676C>T(p.Ala559Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00123 in 1,614,020 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A559T) has been classified as Uncertain significance.
Frequency
Consequence
NM_001044.5 missense
Scores
Clinical Significance
Conservation
Publications
- classic dopamine transporter deficiency syndromeInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- SLC6A3-related dopamine transporter deficiency syndromeInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- parkinsonism-dystonia, infantileInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -3 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000578 AC: 88AN: 152216Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000530 AC: 133AN: 250852 AF XY: 0.000471 show subpopulations
GnomAD4 exome AF: 0.00130 AC: 1893AN: 1461686Hom.: 1 Cov.: 33 AF XY: 0.00117 AC XY: 848AN XY: 727162 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000571 AC: 87AN: 152334Hom.: 0 Cov.: 32 AF XY: 0.000510 AC XY: 38AN XY: 74492 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
SLC6A3: BP4 -
Reported as an apparently de novo variant in heterozygous state in male patient with global developmental delay, hypotonia, status epilepticus, and lactic acidosis; however, a second SLC6A3 variant was not identified and additional variants in other genes that may have been responsible for the phenotype were also identified in this patient (PMID: 26931468); Reported in heterozygous state in an individual with bipolar disorder; however, a second SLC6A3 variant was not identified and variant did not segregate with other affected family members (PMID: 10889530); Reported in heterozygous state in two siblings with attention deficit hyperactivity disorder; however, additional clinical information and segregation information was not provided (PMID: 16171832); Reported in heterozygous state in two unrelated patients with autism in published literature; however, the variant was maternally inherited in both cases from unaffected mothers (PMID: 25313507); In silico analysis suggests that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 18614672, 25331903, 20427663, 29559554, 16103889, 16171832, 19590515, 31133547, 34426522, 35317228, 32473160, 33310157, 37238676, 31094705, 37205452, 34000340, 36630507, 34002696, 34104969, 36552823, 36750796, 10889530, 25313507, 38168036, 37987120, 26931468) -
- -
Inborn genetic diseases Uncertain:1
The c.1676C>T (p.A559V) alteration is located in exon 13 (coding exon 12) of the SLC6A3 gene. This alteration results from a C to T substitution at nucleotide position 1676, causing the alanine (A) at amino acid position 559 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Classic dopamine transporter deficiency syndrome Uncertain:1
- -
See cases Uncertain:1
- -
Parkinsonism-dystonia, infantile Uncertain:1
This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 559 of the SLC6A3 protein (p.Ala559Val). This variant is present in population databases (rs28364997, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with bipolar disorder, attention-deficit hyperactivity disorder (ADHD), speech disfluency, infantile encephalopathy, and/or autism-spectrum disorder (ASD) (PMID: 10889530, 16171832, 19590515, 25313507, 26931468). ClinVar contains an entry for this variant (Variation ID: 290889). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC6A3 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects SLC6A3 function (PMID: 18614672, 20427663, 25313507, 25331903). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at